For the second time in four months, the FDA has issued a warning letter to a supplier of active pharmaceutical ingredients for failing to follow regulatory manufacturing standards. The move comes as the agency attempts to step up oversight of the pharmaceutical supply chain, notably in China, where the company first attracted FDA attention. more
No comments:
Post a Comment